Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack
NCT00510419 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this research study is to evaluate an investigational auto-injector system for delivering sumatriptan under the skin for a single migraine attack. The study could take approximately 5 weeks and will include about 3 office visits to the study doctor, the patient will be contacted every 2 weeks until the patient experiences a migraine and uses the auto-injector. The last visit will be done by a telephone follow-up call.
Conditions Studied
Interventions
- DRUG "Investigational"Auto-injector (sumatriptan succinate)
Study Locations (10)
Texas
- Anodyne Headache and Pain Care — Dallas
- Houston Headache Clinic — Houston
- Road Runner Research, LTD — San Antonio
California
- San Francisco Clinical Research Center — San Francisco
Connecticut
- New England Center for Headache — Stamford
Illinois
- Diamond Head Clinic — Chicago
Michigan
- Michigan Head Pain & Neurological Institute — Ann Arbor
Missouri
- Clinvest — Springfield
Pennsylvania
- University of Pittsburgh Headache Center — Pittsburgh
Tennessee
- Wesley Headache Clinic — Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2007-07 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00510419
The ClinicalTrials.gov registry entry for NCT00510419 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention — of which "Investigational"Auto-injector (sumatriptan succinate) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00510419 reports 10 study locations spanning 8 distinct geographic areas — top geographies include Texas, California, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00510419 about?
NCT00510419 is a clinical study titled "A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack". The purpose of this research study is to evaluate an investigational auto-injector system for delivering sumatriptan under the skin for a single migraine attack. The study could take approximately 5 weeks and will include about 3 office visits to the study doctor, the patient will be contacted ever...
What is the current status of trial NCT00510419?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 73 participants. The study started on 2007-07. Estimated completion is 2007-12.
What conditions does trial NCT00510419 study?
This clinical trial studies the following conditions: Migraine. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00510419?
The interventions under investigation include: "Investigational"Auto-injector (sumatriptan succinate) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00510419?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00510419 being conducted?
This trial has 10 study locations across California, Connecticut, Illinois, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.